CompletedNCT04103892
A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Researchers compared CLE-100 and placebo to find out how the approaches affected depression symptoms in people with depression.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared CLE-100 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Bentonville and 45 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: September 5, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 146
- Sponsor
- Clexio Biosciences Ltd.
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04103892
- Official title
Show the full official title
A Two-Part Study of CLE-100 as an Adjunct Therapy in Subjects With Major Depressive Disorder
Get this study by email
Recruitment & locations
CompletedBentonville, United States · Little Rock, United States · Anaheim, United States
40 more locations
- Bellflower, United States
- Lafayette, United States
- Oakland, United States
- Oceanside, United States
- Riverside, United States
- Santa Ana, United States
- Santa Rosa, United States
- Torrance, United States
- Denver, United States
- Hialeah, United States
- Miami, United States
- Miami Gardens, United States
- Orlando, United States
- Atlanta, United States
- Decatur, United States
- Marietta, United States
- Baltimore, United States
- Rockville, United States
- Boston, United States
- Dearborn Heights, United States
- St Louis, United States
- Lincoln, United States
- Las Vegas, United States
- Marlton, United States
- Toms River, United States
- New York, United States
- Staten Island, United States
- Hickory, United States
- Raleigh, United States
- Middleburg Heights, United States
- North Canton, United States
- Media, United States
- Philadelphia, United States
- Fort Worth, United States
- Houston, United States
- Missouri City, United States
- Plano, United States
- Draper, United States
- Bellevue, United States
- San Juan, Puerto Rico
Questions about this study
What did researchers investigate?
Researchers compared CLE-100 and placebo to find out how the approaches affected depression symptoms in people with depression.
Who is behind this study?
The study sponsor is Clexio Biosciences Ltd.
Did this study involve medication?
Yes. The study involved medication, including CLE-100 and placebo.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
